# Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

> **NCT04734548** · PHASE1,PHASE2 · COMPLETED · sponsor: **aptaTargets S.L.** · enrollment: 151 (actual)

## Conditions studied

- Stroke
- Acute Stroke
- Ischemic Stroke

## Interventions

- **DRUG:** ApTOLL
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04734548
- **Lead sponsor:** aptaTargets S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-28
- **Primary completion:** 2022-07-25
- **Final completion:** 2022-09-07
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04734548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04734548, "Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04734548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*